GSA Capital Partners LLP Sells 34,130 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

GSA Capital Partners LLP decreased its stake in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 18.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 147,932 shares of the company’s stock after selling 34,130 shares during the period. GSA Capital Partners LLP owned about 0.19% of Tenaya Therapeutics worth $286,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TNYA. RA Capital Management L.P. grew its position in Tenaya Therapeutics by 4.5% during the first quarter. RA Capital Management L.P. now owns 5,755,050 shares of the company’s stock valued at $30,099,000 after buying an additional 247,703 shares during the period. Vanguard Group Inc. raised its holdings in Tenaya Therapeutics by 16.4% in the 1st quarter. Vanguard Group Inc. now owns 2,862,916 shares of the company’s stock worth $14,973,000 after purchasing an additional 403,472 shares during the period. Integral Health Asset Management LLC raised its holdings in Tenaya Therapeutics by 3.3% in the 2nd quarter. Integral Health Asset Management LLC now owns 2,325,000 shares of the company’s stock worth $7,208,000 after purchasing an additional 75,000 shares during the period. abrdn plc purchased a new position in Tenaya Therapeutics during the third quarter valued at $1,063,000. Finally, Bank of New York Mellon Corp grew its holdings in Tenaya Therapeutics by 12.3% during the second quarter. Bank of New York Mellon Corp now owns 237,597 shares of the company’s stock valued at $737,000 after purchasing an additional 26,103 shares during the period. Institutional investors own 90.54% of the company’s stock.

Tenaya Therapeutics Trading Up 10.2 %

Shares of Tenaya Therapeutics stock opened at $2.38 on Friday. The stock’s fifty day moving average price is $2.02 and its 200-day moving average price is $2.87. The firm has a market cap of $188.54 million, a P/E ratio of -1.65 and a beta of 2.34. Tenaya Therapeutics, Inc. has a 12 month low of $1.61 and a 12 month high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.07. Analysts forecast that Tenaya Therapeutics, Inc. will post -1.35 earnings per share for the current year.

Analysts Set New Price Targets

TNYA has been the subject of several analyst reports. Piper Sandler reissued an “overweight” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Canaccord Genuity Group restated a “buy” rating and set a $16.00 price objective on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Chardan Capital cut their price target on Tenaya Therapeutics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Finally, Leerink Partners reiterated an “outperform” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Tenaya Therapeutics presently has an average rating of “Buy” and a consensus price target of $14.75.

Tenaya Therapeutics Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.